Essex Bio-Technology Limited (1061.HK)

2.470 -0.010 (-0.40%) As of 10:20AM HKT. Market open.

Essex Bio-Technology Limited

No. 88 Keji 6th Road
Hi-Tech Zone
Zhuhai
China
86 75 6391 1188
https://www.essexbio.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 1,481

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Mia Je Ngiam B.Sc.	Founder & Chairman	3.23M	N/A	1955
Mr. Haizhou Fang	MD & Executive Director	1.74M	N/A	1966
Mr. Hian Leng Ngiam	Executive Director & Deputy MD	1.8M	N/A	1985
Ms. Lai Man Yau A.C.A., C.P.A., M.B.A.	Executive Director & Company Secretary	755.6k	N/A	1964
Dr. Qi Xue	Group Chief Scientific Officer	N/A	N/A	1962

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells bio-pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. The company operates through Ophthalmology and Surgical segments. It researches and develops therapeutic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels. In addition, the company offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and mouth wash Granules; and collagen-based artificial dermis. It has license agreements with Mitotech S.A. and Mitotech LLC for clinical trial of ophthalmic solution containing SkQ1 for dry eye disease; and Shanghai Henlius Biotech Inc. to co-develop a pharmaceutical product that contains an anti-vascular endothelial growth factor as a drug substance, which is intended for the treatment of exudative (wet) age-related macular degeneration. The company was founded in 1990 and is headquartered in Zhuhai, China.

Corporate governance

Essex Bio-Technology Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.